Fig. 9
From: MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage
Demonstration of cross-regulation moments of common target genes for certain microRNAs (miRNAs) during non-traumatic intracerebral hemorrhage (ICH). MiRNAs highlighted in blue demonstrate a positive therapeutic effect on the main pathogenetic links of ICH as a decrease in the permeability of the blood-brain barrier (BBB) and edema, inflammation, generation of reactive oxygen species (ROS) and apoptosis); miRNAs that are highlighted in red show the opposite effect, as an increase in the permeability of the BBB and edema, inflammation, generation of ROS and apoptosis. Notes: PIK3R2, Phosphatidylinositol 3-kinase regulatory subunit beta; IL-6, Interleukin 6; TNF-a, Tumor necrosis factor alpha; IL‐1β, Interleukin 1 Beta; MMP-2, Matrix metalloproteinase 2; MMP-9, Matrix metalloproteinase 9; COX-2, Cyclooxygenase-2; ZO-1, Zonula occludens-1; Nrf2, Nuclear factor erythroid 2–related factor 2; KLF-4, Krüppel-like factor 4; TRAF6, TNF receptor associated factor 6; P53, tumor protein p53; SLC7A11, Cystine/glutamate transporter; GPX4, Glutathione peroxidase 4; FOXO4, Forkhead box O4; Bcl-2, B-cell leukemia/lymphoma 2; 4933404O12Rik, RIKEN cDNA 4933404O12; Sh2b3, SH2B adaptor protein 3; ERK1/2, Extracellular signal-regulated kinase 1/2; CLSTN3, Calsyntenin 3; SOX10, SRY-box transcription factor 10; ACSL4, Acyl-CoA synthetase long chain family member 4; MTF1, Metal regulatory transcription factor 1; ARE, Antioxidant responsive element; PHLPP2, PH domain and leucine rich repeat protein phosphatase 2; MLLT1, Myeloid/lymphoid or mixed lineage leukemia translocated to 1; PI3K, Phosphoinositide 3-kinases; Akt, RAC-alpha serine/threonine-protein kinase; CLCN3, Chloride voltage-gated channel 3